Join Growin Stock Community!

Vaxcyte, inc.PCVX.US Overview

US StockHealthcare
(No presentation for PCVX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

PCVX AI Insights

PCVX Overall Performance

PCVX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PCVX Recent Performance

-1.00%

Vaxcyte, inc.

0.05%

Avg of Sector

-0.31%

S&P500

PCVX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

PCVX Key Information

PCVX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

PCVX Profile

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Price of PCVX

PCVX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PCVX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.34
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.98
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.34
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.98
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is PCVX's latest earnings report released?

    The most recent financial report for Vaxcyte, inc. (PCVX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PCVX's short-term business performance and financial health. For the latest updates on PCVX's earnings releases, visit this page regularly.

  • How much debt does PCVX have?

    As of the end of the reporting period, Vaxcyte, inc. (PCVX) had total debt of 117.48M, with a debt ratio of 0.04. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does PCVX have?

    At the end of the period, Vaxcyte, inc. (PCVX) held Total Cash and Cash Equivalents of 173.96M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is PCVX's EPS continuing to grow?

    According to the past four quarterly reports, Vaxcyte, inc. (PCVX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.8. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of PCVX?

    Vaxcyte, inc. (PCVX)'s Free Cash Flow (FCF) for the period is -233.25M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 64.93% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of PCVX?

    The latest valuation data shows Vaxcyte, inc. (PCVX) has a Price-To-Earnings (PE) ratio of -11.52 and a Price/Earnings-To-Growth (PEG) ratio of -0.4. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.